PRESS RELEASES
June 16, 2020 – Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001
April 27, 2020 – Ichor’s TriGrid System to be used for delivery in non-human primates of a COVID-19 DNA vaccine being developed by the Naval Medical Research Center.
February 3, 2020 – Ichor Partner Scancell Receives SCIB1 Investigational New Drug (IND) Application Approval to Proceed – Phase 2 clinical trial to commence in US
May 9, 2019 – AbCellera Announces Partnership with NIAID Vaccie Research Center and Ichor Medical Systems to Tackle Pandemic Viral Outbreaks
March 26, 2019 – Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform
August 21, 2018 – Ichor Medical Systems Announces Utilization of Its Investigational TriGrid Delivery System in a Clinical Trial Evaluating GX-188E Vaccine Combined with a Checkpoint Inhibitor for Treatment of Cervical Cancer
June 4, 2018 – Ichor Medical Systems Announces First in Human Administration with Its Next Generation TriGrid System of a DNA Vaccine for Chronic Hepatitis B in Development
April 5, 2016 – FIT Biotech Oy: Finnish FIT Biotech and US Ichor to collaborate on new cost effective infectious disease treatment
June 2, 2015 – Ichor partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical Trial in Stage III and IV melanoma patients
April 13, 2015 – Ichor Medical Systems Announces Strategic Collaboration with Johnson & Johnson Innovation to Develop and Commercialize Immunotherapies Delivered with TriGrid® Electroporation Device for Chronic Hepatitis B
November 17, 2014 – Ichor Medical Systems Awarded DARPA Contract for Development of TriGrid® Platform for Passive Immunization
June 2, 2014 – Update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
May 7, 2014 – Flextronics Partners with Ichor Medical Systems to Provide Supply Chain Solutions, Including Design and Manufacturing Services
February 5, 2014 – Ichor Enters into an Agreement with Pfizer to Develop Electroporation Devices for Use in Therapeutic Cancer Vaccine Regimens
April 30, 2013 – Ichor Medical Systems Awarded Contract for Further Development of Broad Vaccine for Biodefense Pathogens
December 6, 2012 – Ichor partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical Trial Preliminary Evidence of Immune Response and Clinical Benefit
December 19, 2011 – IAVI and Partners Initiate AIDS Vaccine Trial in Africa
April 18, 2011 – US Department of Defense Awards Grant to Ichor Medical Systems to Evaluate Skin Electroporation Device for Delivery of Multi-agent DNA Vaccines
January 5, 2011 – Profectus Biosciences Announces Initiation of Clinical Trial of IL-12 Enhanced Therapeutic HIV DNA Vaccine Delivered Using Electroporation
September 23, 2010 – Vaxonco’s EP1300 Epitope-Based DNA Vaccine for Malaria Delivered by Ichor’s TriGrid® Electroporation Enters Phase I Trial
July 26, 2010 – Ichor Medical Systems Awarded Contract to Further Development of Vaccine for Biodefense Pathogen
June 15, 2010 – SCIB1 Phase I Trial Commences – First Patient Treated
May 5, 2010 – Clinical Trial Approval for SCIB1 Melanoma Vaccine Study
March 2, 2010 – Ichor Medical Systems and Profectus Biosciences Enter into an Agreement for Use of TriGrid® Electroporation Device to Develop Multiple DNA Vaccines
February 2, 2010 – Clinical Trial Application for SCIB1 melanoma vaccine
November 30, 2009 – Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses when the Vaccine is Delivered by Electrical Impulses
August 5, 2009 – Ichor Medical Systems Awarded $3.3 Million NIH Grant to Develop Alzheimer’s Disease Vaccine
July 16, 2009 – Scancell Licenses TriGrid® Electroporation Device from Ichor Medical Systems
March 10, 2008 – Pharmexa and Ichor Medical Systems Enter into an Agreement to Co-develop Multiple DNA Vaccines Delivered by Electroporation
March 4, 2008 – Ichor Melanoma Vaccine Clinical Trial Moves to the Highest Dose Level
October 1, 2007 – Ichor Medical Systems’ TriGrid® Selected as Delivery Platform in Collaboration to Test Preventative HIV Vaccine
August 6, 2007 – Navy Partners with Ichor Medical Systems to Develop a Vaccine for Anthrax and Plague
May 14, 2007 – FDA Approves Phase I Clinical Trial Using Ichor’s TriGrid® System and DNA Vaccine for Melanoma Developed at Sloan-Kettering
March 26, 2007 – Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice
March 5, 2007 – United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine
December 18, 2006 – Pharmexa-Epimmune and Ichor Medical Systems Enter into a Collaborative Agreement